Harvard stem cell scientists have discovered that the clump of cells that gives rise to the embryonic heart also contains cells that form the heart’s plumbing, such as the aorta and the other great vessels.
HSCI Executive Committee member Lee Rubin is one of seven scientists selected by biotech leader Biogen Idec to identify and develop new approaches for treating amyotrophic lateral sclerosis (ALS) - more commonly known as Lou Gehrig's disease. Rubin and the other six scientists at Harvard, Yale, Columbia, and Rockefeller will form a consortium to bring to bear their complementary research interests, talents, and areas of expertise on the hitherto untreatable and fatal neurodegenerative disease.
The Harvard Stem Cell Institute (HSCI) invites applications for Pilot Grant funding for 2013 under the NIH-funded P01 grant "Dissecting the establishment and regulation of human pluripotency" (PI Alex Meissner, Harvard Department of Stem Cell and Regenerative Biology). The purpose of this funding program is to provide resources for proof-of-concept studies. These pilot grants are intended to increase our understanding of the basic biology of human pluripotent cells and their utility for translational… Read more about 2013 HSCI call for proposals – P01 pilot grants in human cellular pluripotency
This week the New York Times published an article announcing a $240M investment by Astra Zeneca in Moderna Therapeutics, a start-up company founded by HSCI Principal Faculty Derrick Rossi. As the Times says, "It is one of the largest ever initial payments in a pharmaceutical industry licensing deal that does not involve a drug already being tested in clinical trials."
When the organizers of the upcoming World Regenerative Medicine Congress recently asked scientists and executives across the world in the stem cell and regenerative medicine fields to name “the most influential people in the global stem cell and cell therapy field,” two of HSCI’s leaders were in the top 11.
HSCI's Kevin Eggan has been named a member of a new Stem Cell Research Consortium established by the Cure Alzheimer's Fund. The six consortium scientists, at academic research institutions in the US and Israel will be using techniques pioneered by Eggan, an HSCI Principal Faculty member and a professor in Harvard's Department of Stem Cell and Regenerative Biology, to study in the laboratory the neurons created from the cells of patients at high genetic risk of developing Alzheimer's.